Evidence map›Paper›PMID 29348832›Full record

ArticleOncotarget2017

Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China.

De Zhou, Changqian Bao, Xiujin Ye, Lixia Zhu, Jingjing Zhu, Li Li, Mingyu Zhu, Xiudi Yang, Yanlong Zheng, Xianbo Huang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

De Zhou *Department of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Changqian Bao *Program in Clinical Medicine, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Xiujin YeDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Lixia ZhuDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Jingjing ZhuDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Li LiDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Mingyu ZhuDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Xiudi YangDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Yanlong ZhengDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Xianbo HuangDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Mixue XieDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.
Wanzhuo XieDepartment of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary testicular lymphoma (PTL) is a rare and aggressive form of extranodal lymphoma. Approximately 80-98% of PTLs are diffuse large B-cell lymphoma (PT-DLBCL). The prognosis of DLBCL patients has improved with the addition of rituximab to systemic chemotherapy, but outcomes of PT-DLBCL remain poor. This may be explained by the high rate of relapse in the central nervous system (CNS) and contralateral testis. We analyzed 1,132 newly diagnosed DLBCL patients (37 with PT-DLBCL) who were treated at our hospital between January 2009 and December 2014. Twenty-five patients finished follow-up. We analyzed clinical characteristics, response to chemotherapy, overall survival, and relapse in the CNS and contralateral testis. All patients underwent orchiectomy. The median age was 60 (range: 43-82) years. Eleven patients had stage III/IV disease. Five patients experienced CNS relapse, and three experienced relapse in the contralateral testis. Median overall survival (OS) was not reached at the time of reporting. The 3-year OS rate was 57%. None of the nine patients who received radiotherapy to the contralateral testis experienced relapse in that location. Intrathecal prophylaxis did not reduce the risk of CNS relapse. All five patients who experienced CNS relapse had the germinal center B-cell-like subtype of DLBCL.

Indexed as

diffuse large B-cell lymphomaintrathecal prophylaxisprimary testicular lymphomaradiation therapyRCHOP

Identifiers

PMID29348832
PMCPMC5762517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.